Short answer
RHYTHM PHARMACEUTICALS, INC. (RYTM) filed its fiscal 2025 10-K annual report with the SEC on Feb 26, 2026. It reported revenue of $190M (+45.8% year over year) and net income of −$197M.
- Top risk flagged: Regulatory risk from FDA, EC, MHRA approvals for setmelanotide expansion delays or denials impacting U.S., Canada, EU, UK launch
FY2025 key financial metrics · XBRL
- Revenue
- $190M
- +45.8% YoY
- Net income
- −$197M
- +24.6% YoY
- Operating margin
- -101.2%
- +102.8 pp YoY
- EPS (diluted)
- −$3.11
- +28.3% YoY
- ROE
- -141.3%
- +1058.0 pp YoY
- Operating cash flow
- −$116M
- −1.6% YoY
Source: XBRL data from the RHYTHM PHARMACEUTICALS, INC. (RYTM) FY2025 10-K on SEC EDGAR. USD.
RHYTHM PHARMACEUTICALS, INC. FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business: Development and commercialization of MC4R agonist therapies to treat rare neuroendocrine diseases causing severe obesity and hyperphagia
- New product focus: Anticipated 2026 US launch of IMCIVREE for acquired hypothalamic obesity, plus Phase 3 trial initiation for oral MC4R agonist bivamelagon
- Strategic shift: Expanded pipeline with second-generation MC4R agonists (bivamelagon, RM-718) and emphasis on congenital hypothalamic obesity and Prader-Willi syndrome (PWS)
- Quantitative highlight: 414 employees globally as of February 2026; Phase 3 EMANATE trial topline data expected March 2026 across four rare MC4R genetic disorders
- Noteworthy fact: IMCIVREE approved in 25+ countries; pivotal Phase 3 trial shows 19.8% placebo-adjusted BMI reduction in acquired hypothalamic obesity, addressing a 10,000-patient US population unmet need
Management Discussion & Analysis
- Revenue $422.5M to date from IMCIVREE product sales; commercial launch in US Q1 2021, France March 2022, ongoing growth expected
- Net loss $196.5M in 2025 vs $260.6M in 2024; operating expenses increased with R&D down to $167.3M from $238M, SG&A up to $194.9M from $144.3M
- R&D expenses $167.3M in 2025, decreased from $237.9M in 2024; SG&A expenses $194.9M in 2025, increased from $144.3M in 2024
- Cash and short-term investments approx. $388.9M as of Dec 31, 2025; expected to fund operations for at least 24 months; no specific buybacks or dividends disclosed
- Forward outlook: FDA PDUFA date for bivamelagon in acquired HO March 20, 2026; topline EMANATE Phase 3 data expected March 2026; expansion into PWS and Japan markets anticipated
Risk Factors
- Regulatory risk from FDA, EC, MHRA approvals for setmelanotide expansion delays or denials impacting U.S., Canada, EU, UK launch
- Geopolitical risk due to European operations and recent acquisition of Netherlands-based Xinvento B.V., with CHI program still in discovery phase
- Operational risk from early-stage commercial manufacturing scale-up or reliance on third-party manufacturers for setmelanotide
- Competitive risk from other MC4R pathway therapies and development of RM-718 and bivamelagon, new selective MC4R agonists in clinical trials
- Financial risk from $100M Revenue Interest Financing Agreement requiring up to 11.5% royalties on first $125M net revenues, with payment obligations through 2029
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.